{"id":48566,"date":"2022-09-20T07:02:12","date_gmt":"2022-09-20T05:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/"},"modified":"2022-09-20T07:02:12","modified_gmt":"2022-09-20T05:02:12","slug":"cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/","title":{"rendered":"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction"},"content":{"rendered":"
\n

GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology\u2019s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including the existing facility and all related personnel (the \u201cManufacturing Business Unit\u201d).\n<\/p>\n

<\/a><\/p>\n

\nUnder the terms of an asset purchase agreement between Celyad Oncology and Cellistic, Cellistic agreed to acquire Celyad Oncology\u2019s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for a total consideration of \u20ac6 million. Celyad Oncology\u2019s experienced manufacturing team will join Cellistic. The transaction is subject to a number of customary conditions and is anticipated to close in the fourth quarter of this year.\n<\/p>\n

\n\u201cWe at Cellistic are incredibly excited to welcome this uniquely talented team into our organization,\u201d said Stefan Braam, founder and CEO of Cellistic. \u201cWe\u2019re bringing aboard a group of people whose passion and capabilities align incredibly well with our vision for the future of cell therapy. As a joined force, we have the talent and resources to further accelerate work on our proprietary platforms and the capability to enable Cellistic\u2019s partners to bring iPSC-based allogeneic cell therapies to patients faster.\u201d\n<\/p>\n

\nMichel Lussier, co-founder and interim CEO of Celyad Oncology, said, \u201cWe have focused our efforts on an allogeneic approach for the past few years and our manufacturing facility and staff has been a key element to enable many of our past trials, but has been underutilized in recent years as we mainly used the facility for our autologous candidates. Our current allogeneic programs are better suited for outsourced manufacturing. Through existing materials manufactured at Celyad, we have ensured the means to continue our clinical programs with cryopreserved cells until 2024. Based on this strategy, we are confident that this decision to transfer our manufacturing facility and the staff to Cellistic, who is the perfect company for such an agreement and will allow us to further execute on our business goals in the future.\u201d\n<\/p>\n

\nCellistic will invest substantial capital into the newly acquired 11,000 square foot facility, which will be optimized for its iPSC-based allogeneic cell therapy platforms and processes creating the world\u2019s first purpose-built facility to support customers from cell reprogramming and master cell banking through clinical trial material manufacturing. A team of more than 30 manufacturing, quality and related personnel from Celyad Oncology, all with substantial cell therapy manufacturing and immune-oncology experience, will join Cellistic as part of this transaction.\n<\/p>\n

\nCelyad Oncology will provide additional guidance on the future business strategy of the Company in the fourth quarter of this year.\n<\/p>\n

\nAbout Cellistic<\/b>\n<\/p>\n

\nLaunched in April 2022 as a subsidiary of Ncardia, Cellistic\u2122 specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Its focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development positions the business to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia\u2019s scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC-based cells that deliver quality products at scale. For more information, visit www.cellistic.com<\/a>.\n<\/p>\n

\nAbout Ncardia<\/b>\n<\/p>\n

\nNcardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. The company\u2019s goal is to enable biopharmaceutical companies in drug discovery to accelerate their development processes through the integration of human iPSC technologies. For more information, visit www.ncardia.com<\/a>.\n<\/p>\n

\nAbout Celyad Oncology<\/b>\n<\/p>\n

\nCelyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com<\/a>.\n<\/p>\n

\nCelyad Oncology Forward-Looking Statement<\/b>\n<\/p>\n

\nThis release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the expected closing of the transaction. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties can be found in Celyad Oncology\u2019s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology\u2019s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCellistic Investor and Media Contact:<\/b>
information@cellistic.com<\/a>\n<\/p>\n

\nCelyad Oncology Investor and Media Contact:<\/b>
Sara Zelkovic
\n
Communications & Investor Relations Director
\n
Celyad Oncology
\n
investors@celyad.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology\u2019s Good … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48566","6":"format-standard","7":"category-industry"},"yoast_head":"\nCellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology\u2019s Good ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-20T05:02:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220919005651\/en\/1575887\/21\/Cellistic_Main_Logo_4C.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction\",\"datePublished\":\"2022-09-20T05:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/\"},\"wordCount\":954,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005651\\\/en\\\/1575887\\\/21\\\/Cellistic_Main_Logo_4C.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/\",\"name\":\"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005651\\\/en\\\/1575887\\\/21\\\/Cellistic_Main_Logo_4C.jpg\",\"datePublished\":\"2022-09-20T05:02:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005651\\\/en\\\/1575887\\\/21\\\/Cellistic_Main_Logo_4C.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005651\\\/en\\\/1575887\\\/21\\\/Cellistic_Main_Logo_4C.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/","og_locale":"en_US","og_type":"article","og_title":"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Pharma Trend","og_description":"GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology\u2019s Good ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-20T05:02:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220919005651\/en\/1575887\/21\/Cellistic_Main_Logo_4C.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction","datePublished":"2022-09-20T05:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/"},"wordCount":954,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005651\/en\/1575887\/21\/Cellistic_Main_Logo_4C.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/","url":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/","name":"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005651\/en\/1575887\/21\/Cellistic_Main_Logo_4C.jpg","datePublished":"2022-09-20T05:02:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220919005651\/en\/1575887\/21\/Cellistic_Main_Logo_4C.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220919005651\/en\/1575887\/21\/Cellistic_Main_Logo_4C.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cellistic-and-celyad-oncology-announce-gmp-cell-therapy-manufacturing-operations-transaction\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48566"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48566\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}